Candesartan vs Telmisartan
## Overview
Candesartan and telmisartan are both potent ARBs with once-daily dosing, but they differ in AT1 binding characteristics, half-life, and outcome data. Candesartan has stronger HFrEF evidence; telmisartan has the longest half-life and is safest in renal impairment.
## Mechanism of Action
Candesartan: insurmountable (very slowly reversible) AT1 blockade, very high AT1 affinity. Telmisartan: surmountable AT1 blockade, partial PPAR-gamma agonism.
## Pharmacokinetics
Candesartan (from prodrug cilexetil): half-life ~9 h, dual renal/biliary elimination. Telmisartan: half-life ~24 h, >97% fecal elimination, essentially no renal excretion.
## Clinical Evidence
Candesartan: CHARM program (HFrEF, especially CHARM-Alternative for ACEi-intolerant). Telmisartan: ONTARGET (non-inferior to ramipril in high-risk patients), TRANSCEND (ACEi-intolerant high risk).
## Key Takeaways
- Candesartan: insurmountable AT1 binding, best HFrEF evidence (CHARM program)
- Telmisartan: longest half-life, no renal clearance, PPAR-gamma effect, ONTARGET non-inferior to ramipril
- Both preferred depending on indication: HF vs. CKD/metabolic syndrome
निष्कर्ष
Candesartan is the preferred ARB for HFrEF in ACEi-intolerant patients (CHARM-Alternative). Telmisartan is preferred in CKD (no renal excretion) and in high-risk cardiovascular patients where once-daily adherence and the PPAR-gamma metabolic benefit are desirable. Both are excellent first-line antihypertensives.